Research Grants 1999

Targeting antiapoptotic Genes TRPM-2 and Bcl-2 to improve radiation sensitivity in prostate cancer tumour cells
Dr. Kim Chi, Medical Oncologist at the Prostate Centre, Vancouver General Hospital

These genes cause cells to be resistant to radiation. Blocking these genes may dramatically improve the response of cancer cells to radiation.

Focal adhesion kinase and the invasive phenotype of human prostate cancer
Dr. Armen Aprikian, Uro-Oncologist and Associate Professor in the Department of Surgery, Urology Division, McGill University

Focal adhesion kinase is a key molecule involved in the progression of prostate cancer. Analysis of this molecule will help determine how aggressively a patient's prostate cancer is likely to behave.

Knowing this in advance of any treatment will help patients and their cancer specialists know how aggressively to treat this disease.

Hypoxia in prostate cancer - application of EF5 technologies for prognosis
Dr. Kirsten Skov, Senior Research Scientist at the BC Cancer Research Centre

Hypoxia (low oxygen) in cells makes them resistant to radiation. EF5 is a marker for hypoxia, and permits an analysis of how hypoxia prevents cancers from responding to radiation.

This may lead to improved radiation treatment and helps patients' treatment decisions as physicians will be able to assess which patients may not respond optimally to this choice of treatment.

Establishment of a PSP95 gene driven transgenic mice prostate cancer model
Dr. Jim Xuan, Assistant Professor in the Department of Surgery, University of Western Ontario 

PSP95 is a molecule, which seems to be present only in the prostate, and is secreted into the serum, similar to PSA.

This project will develop a transgenic mouse model that contains the gene for PSP95, for study, to determine the effects of this molecule on the development of prostate cancer.

Study the possible role of Selenium and Vitamin E in preventing prostate cancer and to determine the effect of reducing the presence of free radicals in patients undergoing surgery
Dr. Neil Fleshner, Assistant Professor, Department of Surgery, University of Toronto, Sunnybrook and Women's Health Science Centre
 
This work may result in nutritional therapy to prevent prostate cancer and to improve the results of treatment for those who already have prostate cancer.





Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
BRCA2 gene implicated in rare but lethal prostate cancer

January 9, 2017 – TORONTO, ON – Canadian scientists have discovered a link between an inherited mutation in the BRCA2 gene and a deadly form of prostate cancer.
More

Scientists identify DNA signature linked to prostate cancer severity

January 9, 2017 – TORONTO, ON – The Canadian Prostate Cancer Genome Network (CPC-GENE) has published findings from the world’s most comprehensive genetic analysis of prostate cancer tumours in the journal Nature.
More

Thank You to our Canadian Mo Bros and Sistas!

TORONTO, December 1, 2016 - Prostate Cancer Canada congratulates the more than 500,000 Mo Bros and Mo Sistas worldwide who participated in this year's Movember campaign.
More


Click here for news archive